Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3 Tumor-Agnostic 1 Thoracic 1 Sarcoma 1 Lymphoid 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Dermatologic 1

Conditions

Endometrial Neoplasms 1

Interventions

Carboplatin 66 Paclitaxel 54 pembrolizumab 49 Cyclophosphamide 34 Cisplatin 28 Bevacizumab 26 Nivolumab 21 Gemcitabine 18 fludarabine 17 liposomal doxorubicin 15 Topotecan 15 aldesleukin 13 Filgrastim 12 olaparib 11 Interleukin-2 11 Docetaxel 11 Peripheral Blood Stem Cell Transplantation 10 durvalumab 9 Taxes 9 Specimen Handling 9 Oxaliplatin 8 fludarabine phosphate 7 epacadostat 7 Magnetic Resonance Spectroscopy 7 Ipilimumab 7 Injections 7 rucaparib 6 niraparib 6 lenvatinib 6 cemiplimab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Tiragolumab × Gynecologic × Clear all

NCT04486352 2026-04-01

EndoMAP

Alliance Foundation Trials, LLC.

Phase 1/2 Recruiting

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡